Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Plunder and stowaways: incorporation of cellular proteins by enveloped viruses.

Cantin R, Méthot S, Tremblay MJ.

J Virol. 2005 Jun;79(11):6577-87. Review. No abstract available.

PMID:
15890896
2.

[HIV-1, a very Vif virus].

Schwartz O.

Med Sci (Paris). 2004 Feb;20(2):139-41. French. No abstract available.

PMID:
14997428
3.

New insights into the role of Vif in HIV-1 replication.

Schröfelbauer B, Yu Q, Landau NR.

AIDS Rev. 2004 Jan-Mar;6(1):34-9. Review.

PMID:
15168739
4.

HIV-1 Vif versus APOBEC3G: newly appreciated warriors in the ancient battle between virus and host.

Argyris EG, Pomerantz RJ.

Trends Microbiol. 2004 Apr;12(4):145-8. No abstract available.

PMID:
15116720
5.

HIV: a tough viral nut to crack.

Pomerantz RJ.

Nature. 2002 Aug 8;418(6898):594-5. No abstract available.

PMID:
12167840
6.

A new cellular system opposing HIV infection: implications for gene transfer?

Bushman F.

Mol Ther. 2002 Oct;6(4):441-2. No abstract available.

PMID:
12377183
7.

Death by deamination: a novel host restriction system for HIV-1.

Goff SP.

Cell. 2003 Aug 8;114(3):281-3. Review.

PMID:
12914693
8.

The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K.

J Virol. 2003 Nov;77(21):11398-407.

PMID:
14557625
9.

Good to CU.

Gu Y, Sundquist WI.

Nature. 2003 Jul 3;424(6944):21-2. No abstract available.

PMID:
12840737
10.

The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Sheehy AM, Gaddis NC, Malim MH.

Nat Med. 2003 Nov;9(11):1404-7. Epub 2003 Oct 5.

PMID:
14528300
11.

APOBEC-mediated viral restriction: not simply editing?

Holmes RK, Malim MH, Bishop KN.

Trends Biochem Sci. 2007 Mar;32(3):118-28. Epub 2007 Feb 15. Review.

PMID:
17303427
12.

Virology. Weapons of mutational destruction.

KewalRamani VN, Coffin JM.

Science. 2003 Aug 15;301(5635):923-5. No abstract available.

PMID:
12920286
13.

Recent insights into HIV-1 Vif.

Navarro F, Landau NR.

Curr Opin Immunol. 2004 Aug;16(4):477-82. Review.

PMID:
15245742
14.

APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.

Franca R, Spadari S, Maga G.

Med Sci Monit. 2006 May;12(5):RA92-8. Review.

PMID:
16641889
15.

[How Vif regulates the infectivity of HIV-1].

Takaori-Kondo A.

Seikagaku. 2004 Dec;76(12):1569-73. Review. Japanese. No abstract available.

PMID:
15675371
16.

[The innate antiretroviral defense of human cells, based on the DNA editing].

Pupecka M, Pacak A.

Postepy Biochem. 2006;52(3):247-52. Review. Polish.

PMID:
17201059
17.

HIV-1 Vif: counteracting innate antiretroviral defenses.

Cullen BR.

Mol Ther. 2003 Oct;8(4):525-7. No abstract available.

PMID:
14565218
18.

APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.

Alce TM, Popik W.

J Biol Chem. 2004 Aug 13;279(33):34083-6. Epub 2004 Jun 23.

PMID:
15215254
19.

HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Stopak K, de Noronha C, Yonemoto W, Greene WC.

Mol Cell. 2003 Sep;12(3):591-601.

PMID:
14527406
20.

Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.

Schröfelbauer B, Yu Q, Zeitlin SG, Landau NR.

J Virol. 2005 Sep;79(17):10978-87.

PMID:
16103149

Supplemental Content

Support Center